The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Glofitamab and epcoritamab in the real-world setting: a UK multi-center retrospective analysis
In this video, Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses the efficacy and tolerability of bispecific antibodies (epcoritamab and glofitamab) in a real-world cohort of patients with non-Hodgkin lymphoma (NHL) in the United Kingdom. Dr Osborne highlights the encouraging efficacy of these agents in a high-risk patient population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So we have presented our real-world data for bispecifics in the UK. We had a cohort of 138 glofitamab patients and 38 epcoritamab patients. And essentially we saw that our cohort was a high-risk cohort median of three prior lines of treatment so most of our patients were having this treatment fourth line and beyond. And yet despite this high-risk group we did see a complete metabolic response rate of about 27% and we saw that this was durable at 12 months in more than three quarters of patients...
So we have presented our real-world data for bispecifics in the UK. We had a cohort of 138 glofitamab patients and 38 epcoritamab patients. And essentially we saw that our cohort was a high-risk cohort median of three prior lines of treatment so most of our patients were having this treatment fourth line and beyond. And yet despite this high-risk group we did see a complete metabolic response rate of about 27% and we saw that this was durable at 12 months in more than three quarters of patients. So I think that we were pleased with the response rates in such a high-risk group.
I also think it was quite interesting when we looked at the patients who had had prior CAR-T, so 60% of our cohort had prior CAR-T. And as we maybe would expect, the patients who had been failed by CAR-T did have a lower response rate, so our CMR rate for that group was 24% compared to 32% if patients hadn’t had prior CAR-T.
And then the other thing that we found quite interesting is that we found that our patients responded less well if they had had prior bendamustine, particularly if it was within six months of the treatment with the bispecific. So I think that all of these things we need to continue to look at so it will help us with deciding about treatment sequencing.
And the other data obviously is toxicity data and our toxicity data is very similar to what we’ve seen in the pivotal studies. So about a third of patients had cytokine release syndrome but it was mainly low grade with 16% having grade 2 and just 5% grade 3, and we saw ICANS quite infrequently of about four to five percent. So I’m pleased with our UK real-world cohort, it’s a large cohort and we’re going to continue to collect these data so that it can guide us about use of bispecific antibodies and hopefully that CMR rate will improve when we’re seeing it used more and more in a third line setting where it has license.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria: Roche, Takeda, Pfizer, Kite Gilead, Astra Zeneca, Novartis, Kyowa Kirin, Incyte, Janssen, BMS; Membership on an entity’s Board of Directors or advisory committees: Roche, Takeda, Kite Gilead, Kyowa Kirin, Servier, Incyte, Janssen, BMS, MSD, Beigene, Autolus, Sobi, Syneos.
